Differentiated Thyroid Cancers 11-20 Mm in Diameter Have Clinical and Histopathologic Characteristics Suggesting Higher Aggressiveness Than Those < or =10 Mm
Overview
Authors
Affiliations
Objective: To compare characteristics and outcomes of differentiated thyroid cancers < or =10 mm with those 11-20 mm in diameter.
Design: Retrospective chart review of 426 patients with thyroid carcinoma < or =20 mm diagnosed and treated between 1990 and 2004 in one university clinic.
Main Outcomes: Lymph node metastases were more frequent at diagnosis in 11-20 mm than in < or =10 mm cancers (p < 0.001). The prevalence of distant metastases did not differ between < or =10 mm and 11-20 mm cancers. One hundred and thirty-three patients (73%) with tumors 11-20 mm were disease free 2 years after 131I treatment, and no recurrence has been observed over 2-14 years of follow-up. Forty-one patients (22%) with cancers 11-20 mm (N1 or M1) required 2-4 years to become disease free. Neck lymph node recurrence was observed in nine patients (4.9%) 4 months to 14 years after surgery and (131)I therapy. Four patients (1.6%) with cancers < or =10 mm in diameter had cancer recurrence (p = 0.05 compared to the 11-20 mm cancers). Based on the presence of distant metastases at diagnosis and recurrence of disease during follow-up, cancers 11-20 mm in diameter seemed more aggressive than those < or =10 mm (p < 0.05).
Conclusion: Cancers 11-20 mm seem more aggressive than those < or =10 mm.
Tatli Dogan H, Kilicarslan A, Caglayan A, Sungu N Eurasian J Med. 2024; 56(2):98-101.
PMID: 39128065 PMC: 11332271. DOI: 10.5152/eurasianjmed.2024.23182.
Chen J, Zhang D, Fang L, He G, Gao L J Int Med Res. 2020; 48(4):300060520920036.
PMID: 32326781 PMC: 7221171. DOI: 10.1177/0300060520920036.
Effects of tumor size on prognosis in differentiated thyroid carcinoma smaller than 2 cm.
Zhang T, Li C, Wen S, Huang D, Sun G, Zhu Y Oncol Lett. 2019; 17(5):4229-4236.
PMID: 30944617 PMC: 6444283. DOI: 10.3892/ol.2019.10088.
Wang J, Liu J, Pan H, Jiang C, Liu S, Zhu Z Cancer Manag Res. 2018; 10:3867-3873.
PMID: 30288118 PMC: 6163014. DOI: 10.2147/CMAR.S167774.
Liu C, Ming J, Zeng W, Wang S, Xiong Y, Zhao Q Oncotarget. 2017; 8(41):70777-70787.
PMID: 29050318 PMC: 5642593. DOI: 10.18632/oncotarget.19988.